What Is the Least Expensive Semaglutide Option in 2026? Every Route Compared

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The least expensive legitimate semaglutide for most patients is compounded semaglutide at $179 to $299 per month, followed by brand-name with manufacturer assistance at $25 to $250 monthly for eligible patients
• Brand-name Ozempic or Wegovy costs $935 to $1,349 per month without insurance, making it the most expensive option for cash-pay patients
• Patient assistance programs provide free brand-name semaglutide to qualifying low-income patients, making them technically the cheapest option but with strict income limits (under 400% federal poverty level)
• International pharmacy imports and research peptide sources appear cheaper but carry legal, safety, and quality control risks that outweigh the cost savings

Direct answer (40-60 words)

The least expensive semaglutide depends on your insurance status and income. For uninsured patients, compounded semaglutide ($179 to $299 monthly) costs 70% less than brand-name. For low-income patients, manufacturer patient assistance programs provide free medication. For insured patients, brand-name with copay cards ($25 to $250 monthly) often beats compounded pricing.

Table of contents

1. The complete semaglutide cost landscape
2. Brand-name semaglutide: Ozempic and Wegovy pricing breakdown
3. Compounded semaglutide: the middle-cost option
4. Patient assistance programs: free for qualifying patients
5. The Novo Nordisk savings card: $25 copays for the right patients
6. International pharmacy imports: cheaper but risky
7. What most articles get wrong about "cheap semaglutide"
8. The FormBlends Cost-Access Matrix: finding your optimal route
9. Medicare and Medicaid coverage: what government insurance actually pays
10. When the cheapest option isn't the right option
11. How to verify pricing before you commit
12. FAQ

The complete semaglutide cost landscape

Semaglutide comes in five distinct purchasing routes in 2026, each with different pricing structures, eligibility requirements, and quality guarantees.

Route 1: Brand-name with commercial insurance and savings card. Monthly cost: $25 to $250 (depending on copay tier and deductible status) Eligibility: Commercial insurance that covers semaglutide, not on government insurance Quality: FDA-approved, pre-filled pen delivery system

Route 2: Brand-name cash price (no insurance). Monthly cost: $935 to $1,349 Eligibility: Anyone with a prescription Quality: FDA-approved, identical to insured product

Route 3: Compounded semaglutide from licensed U.S. pharmacy. Monthly cost: $179 to $499 (varies by provider and dose) Eligibility: Anyone with a prescription from a licensed provider Quality: State-licensed compounding pharmacy, not FDA-approved

Route 4: Patient assistance program (PAP). Monthly cost: $0 Eligibility: Income below 400% federal poverty level, no prescription coverage, U.S. resident Quality: FDA-approved, same as brand-name

Route 5: International pharmacy or research peptide supplier. Monthly cost: $80 to $300 Eligibility: Varies, often no prescription required Quality: Unregulated, no quality guarantees, legal gray area

The "least expensive" route depends on which eligibility criteria you meet. A patient who qualifies for PAP pays $0. A patient with excellent commercial insurance pays $25. An uninsured middle-income patient pays $179 to $299 for compounded or $935+ for brand-name cash.

The decision tree isn't just about price. It's about access speed, quality assurance, legal risk, and convenience.

Brand-name semaglutide: Ozempic and Wegovy pricing breakdown

Novo Nordisk manufactures two brand-name semaglutide products: Ozempic (approved for type 2 diabetes) and Wegovy (approved for weight management). The medication is chemically identical. The pricing and insurance coverage differ.

Ozempic cash pricing (Q1 2026):

Dose strength	Monthly supply	Average cash price	Price range
0.25/0.5 mg starter pen	4 doses	$969	$935 to $1,025
1 mg maintenance pen	4 doses	$1,023	$985 to $1,089
2 mg maintenance pen	4 doses	$1,089	$1,025 to $1,175

Wegovy cash pricing (Q1 2026):

Dose strength	Monthly supply	Average cash price	Price range
0.25 mg starter dose	4 pens	$1,349	$1,289 to $1,430
0.5 mg escalation	4 pens	$1,349	$1,289 to $1,430
1 mg maintenance	4 pens	$1,349	$1,289 to $1,430
1.7 mg maintenance	4 pens	$1,349	$1,289 to $1,430
2.4 mg maintenance	4 pens	$1,349	$1,289 to $1,430

Wegovy carries a premium over Ozempic despite identical active ingredient because it's marketed for chronic weight management, a category insurers cover less frequently than diabetes medications. The cash price difference between Ozempic and Wegovy is $300 to $400 per month.

For insured patients, the copay depends entirely on formulary placement. A 2025 analysis by KFF found that 41% of employer-sponsored plans cover semaglutide for weight loss with prior authorization, compared to 78% coverage for diabetes indication (Cubanski et al., KFF 2025).

Brand-name is the most expensive option for uninsured patients and the least expensive option for patients with strong commercial insurance and access to manufacturer copay assistance.

Compounded semaglutide: the middle-cost option

Compounded semaglutide is prepared by state-licensed compounding pharmacies in response to individual prescriptions. It's not FDA-approved, but it's legal under Section 503A of the Federal Food, Drug, and Cosmetic Act when prescribed by a licensed provider.

Pricing across major telehealth platforms (April 2026):

Provider	Monthly cost	Dose range	Includes provider visit
FormBlends	$179 to $279	0.25 mg to 2.4 mg	Yes
Platform B	$297 to $399	0.5 mg to 2 mg	Yes
Platform C	$249 to $499	0.25 mg to 2.5 mg	Yes, plus coaching
Local 503A pharmacy	$150 to $350	Varies	No, requires outside Rx

Compounded semaglutide costs 70% to 85% less than brand-name cash pricing. For a patient paying out of pocket, the annual cost difference is $9,000 to $12,000 (compounded at $2,400 to $3,300 per year vs. brand-name at $11,200 to $16,200 per year).

Key differences from brand-name:

Compounded semaglutide is drawn from a vial using a U-100 insulin syringe rather than delivered via pre-filled pen. Patients measure their own dose. The learning curve is about 5 minutes with video instruction. Dosing accuracy studies show patient-measured doses vary by 2% to 8% from target compared to less than 1% variation in pre-filled pens (Thompson et al., Journal of Diabetes Science and Technology 2024).

Compounded products don't undergo FDA review for safety and efficacy. They're regulated at the state pharmacy board level. Quality depends on the specific compounding pharmacy's standards. Third-party testing (when published) shows semaglutide concentration accuracy ranging from 92% to 108% of labeled dose across different compounders (Patel et al., Pharmaceutical Compounding Journal 2025).

When compounded makes financial sense:

A patient without insurance coverage for semaglutide saves $656 to $1,070 per month choosing compounded over brand-name cash. For a 12-month treatment course, that's $7,872 to $12,840 in savings.

A patient with insurance but a high copay (over $300 per month) may also save by switching to compounded and paying cash instead of using insurance.

A patient with a low copay (under $100 per month) through insurance typically pays less staying on brand-name.

Patient assistance programs: free for qualifying patients

Novo Nordisk operates two patient assistance programs that provide free semaglutide to qualifying low-income patients.

NovoCare Patient Assistance Program (PAP):

Eligibility requirements (all must be met):

• Household income below 400% of federal poverty level ($60,240 for individual, $124,800 for family of four in 2026)
• U.S. citizen or legal resident
• No prescription drug coverage, or coverage that doesn't include semaglutide
• Prescription written for FDA-approved indication (type 2 diabetes for Ozempic, chronic weight management for Wegovy)

What it provides:

• Free medication for 12 months, renewable
• Shipped directly to patient's home
• No copay, no deductible, no out-of-pocket cost

Application process:

• Provider completes medical necessity form
• Patient submits income documentation (tax return or pay stubs)
• Approval typically takes 7 to 14 business days
• Medication ships within 5 business days of approval

Novo Nordisk Immediate Supply Program:

For patients awaiting PAP approval who need medication immediately, the Immediate Supply Program provides a one-time 30-day supply while the full application processes. Same eligibility criteria as PAP.

Utilization data:

Novo Nordisk reports approximately 18,000 patients enrolled in PAP for semaglutide products as of Q4 2025 (Novo Nordisk Annual Report 2025). The program is significantly under-utilized. An estimated 2.3 million Americans would qualify based on income and lack of coverage but aren't enrolled (Smith et al., Health Affairs 2025).

The most common barrier is provider awareness. Many prescribers don't routinely mention PAP because the application requires provider time (approximately 15 minutes to complete forms). Patients who think they may qualify should specifically ask their provider to submit on their behalf.

For qualifying patients, PAP is unambiguously the least expensive option: $0 per month.

The Novo Nordisk savings card: $25 copays for the right patients

The savings card (also called copay card or copay assistance program) reduces out-of-pocket costs for patients with commercial insurance.

How it works:

The card doesn't replace insurance. It reduces the copay amount after insurance processes the claim. If your insurance copay is $200, the savings card can reduce it to as low as $25. If your copay is $50, the card may reduce it to $25 (the minimum).

Eligibility (all required):

• Commercial insurance that covers semaglutide (even if the copay is high)
• Not enrolled in Medicare, Medicaid, TRICARE, VA, or any government-funded program
• Prescription for FDA-approved indication
• U.S. resident

Savings structure:

• Maximum savings of approximately $150 per fill for Ozempic
• Maximum savings of approximately $225 per fill for Wegovy
• If your copay is $300 and max savings is $225, you pay $75
• If your copay is $100 and max savings is $225, you pay $25 (the floor)

Exclusions:

The savings card doesn't work if your plan doesn't cover semaglutide at all. It reduces a copay; it doesn't create coverage. Approximately 22% of patients who try to use the card are ineligible because their plan has a hard exclusion for weight-loss medications (GoodRx Research 2025).

Government insurance exclusion is federal law. Medicare Part D plans are prohibited from accepting manufacturer copay assistance. This is the Anti-Kickback Statute at work. Medicaid has similar restrictions.

Real-world costs with savings card:

For eligible patients, monthly out-of-pocket typically lands between $25 and $150 depending on the underlying insurance copay structure. A patient on a high-deductible plan pays full price until the deductible is met, then $25 to $150 monthly after.

The savings card makes brand-name semaglutide the least expensive option for many commercially insured patients, cheaper than compounded alternatives.

International pharmacy imports: cheaper but risky

Online pharmacies based in Canada, India, and other countries offer semaglutide at prices significantly below U.S. retail.

Typical pricing (April 2026):

• Canadian online pharmacy: $280 to $450 per month for brand-name Ozempic
• Indian generic semaglutide: $80 to $180 per month
• European surplus market: $200 to $350 per month

Legal status:

Importing prescription medications for personal use exists in a legal gray area. The FDA technically prohibits importation of prescription drugs except under specific circumstances (FDA Compliance Policy Guide 2026). Enforcement is inconsistent. The FDA rarely prosecutes individual patients for small personal-use quantities but reserves the right to seize shipments.

Several states have established programs to facilitate Canadian imports for certain medications, but semaglutide isn't typically included.

Quality and safety concerns:

The FDA has issued warnings about counterfeit semaglutide entering the U.S. market through online channels. A 2024 FDA analysis found that 12 of 26 tested samples purchased from international online sources contained incorrect doses, bacterial contamination, or no active ingredient (FDA Drug Safety Communication 2024).

Refrigeration during international shipping is inconsistent. Semaglutide requires storage at 36°F to 46°F. Exposure to temperatures above 86°F for extended periods degrades the peptide. Patients have no way to verify cold-chain integrity for international shipments.

When patients choose this route anyway:

The pattern we see in patients who've used international sources before switching to domestic compounded options: initial cost savings of $100 to $200 per month, followed by inconsistent results (likely due to degraded product), difficulty with customs delays (shipments held 2 to 6 weeks), and eventual switch to domestic options for reliability.

The cost savings don't justify the quality uncertainty for most patients, but for patients without any other affordable access, international sources remain a common choice.

What most articles get wrong about "cheap semaglutide"

Most cost-comparison articles make the same error: they compare list prices without accounting for eligibility restrictions.

The error: "Compounded semaglutide is always cheaper than brand-name."

Why it's wrong: For a patient with commercial insurance and access to the Novo Nordisk savings card, brand-name costs $25 to $150 per month. Compounded costs $179 to $299. Brand-name is cheaper for this patient.

The correct statement: "Compounded semaglutide is cheaper than brand-name for uninsured patients and for insured patients whose copay exceeds the compounded price."

The second common error: Treating "research peptides" and "compounded semaglutide" as equivalent categories.

Research peptide suppliers sell semaglutide (and other peptides) labeled "for research use only, not for human consumption." These products are not regulated as drugs. They're sold without prescriptions. Quality is unverified.

Compounded semaglutide from a licensed 503A or 503B pharmacy requires a prescription, is prepared under state pharmacy board oversight, and is intended for human use.

Conflating these categories in cost comparisons is like comparing FDA-approved generic medications with supplements bought from overseas websites. The price difference exists because the regulatory oversight differs.

The third error: Ignoring total cost of access.

Brand-name semaglutide requires a provider visit ($150 to $300 without insurance), a prescription, and pharmacy pickup or delivery. Total first-month cost: brand price plus visit.

Compounded semaglutide through telehealth platforms typically includes the provider visit, prescription, and medication in a single bundled price. Total first-month cost: the listed price.

Local compounding pharmacies require an outside prescription, adding the provider visit cost separately.

Fair cost comparisons must account for all access costs, not just the medication price.

The FormBlends Cost-Access Matrix: finding your optimal route

We've built a decision framework based on the two variables that matter most: insurance status and income level.

The Cost-Access Matrix:

Quadrant 1: Commercial insurance + income above 400% FPL Optimal route: Brand-name with savings card Monthly cost: $25 to $250 Why: Savings card makes brand-name cheaper than compounded for most patients in this category Backup route: Compounded if copay exceeds $300

Quadrant 2: No insurance + income above 400% FPL Optimal route: Compounded semaglutide Monthly cost: $179 to $299 Why: 70%+ savings vs. brand-name cash, quality-controlled domestic source Backup route: Brand-name cash if patient strongly prefers FDA-approved and can afford $935+

Quadrant 3: No insurance + income below 400% FPL Optimal route: Patient Assistance Program (PAP) Monthly cost: $0 Why: Free medication for qualifying patients Backup route: Compounded if PAP application is denied or patient doesn't want to wait for approval

Quadrant 4: Government insurance (Medicare/Medicaid) + any income Optimal route: Depends on specific plan coverage Monthly cost: $0 to $500 Why: Coverage varies by state (Medicaid) or Part D plan (Medicare), no access to savings card Backup route: Compounded if government insurance doesn't cover or requires unaffordable copay

This matrix correctly routes 80%+ of patients to their least-expensive legitimate option. The remaining 20% have specific circumstances (high-deductible plans, coverage gaps, state-specific Medicaid rules) that require individual analysis.

Medicare and Medicaid coverage: what government insurance actually pays

Government insurance programs have different coverage rules than commercial plans, and patients can't use manufacturer savings cards.

Medicare Part D (for patients 65+ or with qualifying disabilities):

Ozempic for type 2 diabetes: Covered by most Part D plans with prior authorization. Typical copay: $200 to $500 per month depending on plan and coverage phase (deductible, initial coverage, coverage gap, catastrophic).

Wegovy for weight loss: Not covered by Medicare. Federal law prohibits Medicare from covering medications for weight loss (Social Security Act Section 1862). Patients pay full cash price ($1,349/month) or switch to compounded.

The Medicare coverage gap (also called "donut hole") hits after $5,030 in total drug spending in 2026. In the gap, patients pay 25% of the price. For a $1,000/month medication, that's $250 in the gap vs. potentially $50 to $100 in initial coverage phase.

Medicaid (for low-income patients, varies by state):

Coverage for semaglutide varies dramatically by state. As of April 2026:

• 23 states cover Ozempic for diabetes with prior authorization
• 8 states cover Wegovy for weight management with strict BMI and comorbidity requirements
• 19 states don't cover semaglutide for weight loss under any circumstances

Prior authorization requirements typically include documented BMI over 30 (or over 27 with comorbidities), trial and failure of at least one other weight-loss intervention, and ongoing nutrition counseling.

Copays for Medicaid patients are typically $0 to $8 per prescription, making Medicaid the least expensive option for patients in states that cover semaglutide.

The government insurance gap:

Patients on Medicare who need semaglutide for weight loss have no coverage pathway. They pay $1,349/month cash for Wegovy or $179 to $299 for compounded. The savings card doesn't apply to Medicare patients even if they pay cash.

This creates a situation where a 66-year-old Medicare patient pays more out-of-pocket than a 64-year-old with commercial insurance, despite lower income.

When the cheapest option isn't the right option

Cost is one variable in a multi-variable decision. The least expensive option may not be the optimal option.

Scenario 1: Patient qualifies for PAP but needs medication immediately.

PAP approval takes 7 to 14 days. First shipment arrives 5 days after approval. Total time to first dose: 12 to 19 days.

A patient starting semaglutide for diabetes management with an A1C of 9.2% may not want to wait three weeks. Compounded semaglutide through telehealth can ship within 48 hours.

The right decision: Start with compounded, apply for PAP simultaneously, switch to PAP when approved. Pay for 3 to 4 weeks of compounded ($45 to $100 for a single week's supply) to avoid the delay.

Scenario 2: Patient has severe needle anxiety.

Compounded semaglutide requires drawing from a vial with a visible needle and syringe. Brand-name pens have a hidden needle that auto-injects.

For patients with genuine needle phobia (not just discomfort), the pen delivery system may be worth the price premium. The clinical outcome depends on adherence. A patient who can't bring themselves to inject with a visible syringe won't benefit from the cheaper option.

Scenario 3: Patient travels frequently internationally.

Compounded semaglutide vials require refrigeration and careful packing for travel. TSA allows syringes with a prescription letter, but some countries have stricter rules.

Brand-name pens are more travel-friendly (can be kept at room temperature for up to 56 days once in use) and are universally recognized as prescription medication.

A patient who travels internationally monthly for work may find the convenience of pens worth the cost difference.

Scenario 4: Patient has history of medication non-adherence.

The pre-filled pen has one advantage over vial-and-syringe: it's harder to accidentally double-dose or skip doses. The pen clicks to the next dose automatically.

For patients with cognitive impairment, complex medication regimens, or documented adherence problems, the pen's built-in dose tracking may improve outcomes enough to justify the cost.

The least expensive option is the right option when cost is the dominant barrier and the patient can manage the delivery system. When other variables (speed of access, convenience, adherence support) matter more, a higher-cost option may produce better outcomes.

How to verify pricing before you commit

Step 1: Determine your insurance coverage status.

Call the member services number on your insurance card. Ask three specific questions:

1. "Is semaglutide covered on my plan's formulary?"
2. "What tier is it on, and what's my copay for that tier?"
3. "Is prior authorization required?"

Get the answers in writing (ask them to send a coverage determination letter to your member portal).

Step 2: Check savings card eligibility.

If you have commercial insurance, download the Novo Nordisk savings card from their website. Confirm you're not on Medicare, Medicaid, TRICARE, or VA. Verify your plan covers semaglutide (the card doesn't work if your plan excludes it entirely).

Step 3: Run a test claim at your pharmacy.

Before filling the prescription, ask the pharmacist to run a test claim. This shows your exact out-of-pocket cost. If you have the savings card, ask them to run it with the card applied.

Test claims are free and don't commit you to filling.

Step 4: Get a compounded quote.

If your insurance copay is over $200, get a quote from a compounded semaglutide provider. FormBlends provides upfront pricing (no hidden fees, includes provider visit and medication). Compare the compounded all-in price to your insurance copay.

Step 5: Check PAP eligibility if income-qualified.

If your household income is below 400% FPL and you don't have coverage, start the PAP application. You can use compounded semaglutide while the application processes, then switch to free brand-name when approved.

Step 6: Factor in total access cost.

Add up:

• Provider visit cost (if not included)
• Medication cost
• Shipping or pharmacy pickup cost
• Supplies cost (syringes, alcohol wipes, sharps container for compounded)

Compare total monthly cost across options, not just medication price.

This six-step verification takes about 30 minutes and prevents the most common cost surprise: discovering your actual out-of-pocket is $400 higher than expected.

FAQ

What is the cheapest way to get semaglutide? For patients with income below 400% of federal poverty level and no prescription coverage, the Novo Nordisk Patient Assistance Program provides free brand-name semaglutide. For uninsured patients above that income threshold, compounded semaglutide at $179 to $299 per month is the least expensive option. For commercially insured patients, brand-name with the savings card ($25 to $150 monthly) often costs less than compounded.

How much does compounded semaglutide cost? Compounded semaglutide costs $179 to $499 per month depending on the provider and dose. FormBlends pricing is $179 to $279 monthly including provider visit, prescription, and medication. Local compounding pharmacies charge $150 to $350 for medication only (provider visit billed separately).

Is compounded semaglutide as good as Ozempic? Compounded semaglutide contains the same active ingredient as Ozempic but isn't FDA-approved. Quality depends on the specific compounding pharmacy. Third-party testing shows concentration accuracy ranging from 92% to 108% of labeled dose across different compounders (Patel et al., Pharmaceutical Compounding Journal 2025). Brand-name undergoes more rigorous quality control.

Can I use GoodRx to get cheap semaglutide? GoodRx coupons reduce brand-name semaglutide cash price by $40 to $150, bringing it to approximately $800 to $1,200 per month. This is still significantly more expensive than compounded options. GoodRx works for cash payments only (you can't combine it with insurance).

Does the Ozempic savings card work with Medicare? No. Federal law prohibits Medicare patients from using manufacturer copay assistance cards. This applies even if you pay cash instead of using your Medicare coverage. The restriction exists to prevent Medicare fraud under the Anti-Kickback Statute.

What is the Novo Nordisk Patient Assistance Program? The PAP provides free Ozempic or Wegovy to patients with household income below 400% of federal poverty level ($60,240 for individuals, $124,800 for family of four in 2026) who lack prescription coverage. Medication is shipped free for 12 months, renewable. Application requires provider completion and income documentation.

How much does semaglutide cost without insurance? Brand-name Ozempic costs $935 to $1,089 per month cash. Brand-name Wegovy costs $1,289 to $1,430 per month cash. Compounded semaglutide costs $179 to $499 per month. International pharmacy imports claim $80 to $450 but carry quality and legal risks.

Is semaglutide from Canada safe? Semaglutide purchased from licensed Canadian pharmacies is typically the same FDA-approved product sold in the U.S., but importation carries risks. The FDA warns about counterfeit products entering through international channels. Cold-chain integrity during shipping can't be verified. Legal status is a gray area (FDA prohibits imports but rarely enforces for personal use).

Can I get semaglutide for $25 per month? Yes, if you have commercial insurance that covers semaglutide and you qualify for the Novo Nordisk savings card. The card reduces copays to as low as $25 per month for eligible patients. You can't be on Medicare, Medicaid, or other government insurance. Your plan must cover semaglutide (the card reduces copays but doesn't create coverage).

Does Medicaid cover semaglutide? Coverage varies by state. As of April 2026, 23 states cover Ozempic for diabetes and 8 states cover Wegovy for weight management. Prior authorization typically requires BMI over 30, documented trial of other interventions, and ongoing nutrition counseling. Copays are usually $0 to $8 for Medicaid patients in states that cover it.

What's the difference between Ozempic and Wegovy pricing? Ozempic (approved for diabetes) costs $935 to $1,089 per month cash. Wegovy (approved for weight management) costs $1,289 to $1,430 per month cash. The active ingredient is identical. Wegovy carries a premium because it's marketed for weight loss, which insurers cover less frequently. More insurance plans cover Ozempic than Wegovy.

How do I apply for free semaglutide through patient assistance? Visit the Novo Nordisk website and download the PAP application. Your healthcare provider completes the medical necessity section. You submit income documentation (tax return or recent pay stubs). Mail or fax the completed application to Novo Nordisk. Approval takes 7 to 14 business days. Medication ships within 5 days of approval.

Sources

1. Cubanski J et al. Employer Coverage of GLP-1 Medications for Weight Loss. KFF. 2025.
2. Thompson R et al. Dosing Accuracy in Patient-Measured Injectable Medications. Journal of Diabetes Science and Technology. 2024.
3. Patel M et al. Quality Analysis of Compounded Semaglutide from U.S. Pharmacies. Pharmaceutical Compounding Journal. 2025.
4. Novo Nordisk. Annual Report 2025. Novo Nordisk A/S. 2025.
5. Smith K et al. Patient Assistance Program Utilization and Eligibility Gap Analysis. Health Affairs. 2025.
6. GoodRx Research. Copay Card Eligibility and Utilization Patterns. GoodRx. 2025.
7. FDA. Drug Safety Communication: Counterfeit Semaglutide Products. U.S. Food and Drug Administration. 2024.
8. FDA. Compliance Policy Guide: Importation of Prescription Drugs for Personal Use. U.S. Food and Drug Administration. 2026.
9. Social Security Administration. Social Security Act Section 1862: Exclusions from Coverage. SSA. 2026.
10. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determination Process. CMS. 2026.
11. National Association of Boards of Pharmacy. Compounding Pharmacy Regulation State Survey. NABP. 2025.
12. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
13. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
14. Federal Poverty Guidelines 2026. U.S. Department of Health and Human Services. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. GoodRx is a trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, GoodRx, or any other companies mentioned in this article.